ClinicalTrials.gov
ClinicalTrials.gov Menu

Molecular Evaluation of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer (MENCA-GC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03425058
Recruitment Status : Recruiting
First Posted : February 7, 2018
Last Update Posted : February 8, 2018
Sponsor:
Information provided by (Responsible Party):
Jiafu Ji, Beijing Cancer Hospital

Brief Summary:
Gastric cancer (GC) is a leading global health problem and is the third most common cause of cancer related death. Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is the mainstay treatment for locally advanced gastric cancer, and variable degrees of tumor regression are observed after nCRT. Treatment strategies, including close surveillance without immediate surgery, have been investigated to spare patients with complete tumor regression from potentially adverse outcomes of radical surgery. However, clinical and radiological assessment of treatment response does not deliver an ideal accuracy of patients identification with complete response. In the present study, we focused on the clinical courses of patients who have developed locally advanced gastric cancer, and investigated the potential clinical utility of the detection of deficient MMR(dMMR), microsatellite instability(MSI) status and the decreasing level of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) as promising biomarkers for the diagnosis and prediction of GC during treatment progress. Twenty milliliters of plasma were collected at 3 time points: before nCRT; after 2 cycles of nCRT; and after surgery. Firefly ctDNA NGS assays were used to track ctDNA mutations previously characterized in paired tumor tissue by massively parallel sequencing (MPS). We investigated whether circulating tumor DNA (ctDNA) detection can reflect tumor response to nCRT and detect minimal residual disease(MRD) after surgery. We compared CTC and ctDNA levels to clinical, radiological and pathological assessment modalities for nCRT response. The results will provide lots of information which may contribute to promote the treatment of GC patients. We want to introduce these strategies into clinical practice if possible.

Condition or disease
Gastric Cancer

Detailed Description:

This study is a single-center observational study on a patient cohort of at least 80 patients with histologically-confirmed locally advanced gastric cancer (LAGC). The protocol used in this study is approved by the Ethics Committee of Beijing Cancer Hospital.

The primary endpoint is the 3-year progression-free survival (PFS) rate. The secondary endpoints are the overall survival (OS) and safety.

Currently, the best treatment for early and mid-stage LAGC patients is resection but even with successful treatment, most patients still relapse and the 5-year survival rate is less than 30%.

For patients with cT4a/T4bN+M0, including T4b、Bulky-N2, primary lesions are not always fully excised during treatment and prognosis for these patients is generally poor. Recent studies, however, have suggested that the inclusion of neoadjuvant chemotherapy (NCT) can improve patient outcomes by: 1) downstaging tumors and increasing the likelihood of curative resection, 2) reducing the prevalence of micro metastases.

Historically, Oxaliplatin and s-1 combination therapy has been shown to be well-tolerated in patients with recurrent or metastatic gastric cancer.

To best evaluate the treatment response of NCT, we plan to investigate the effect of new technologies and assays on the successful prediction of patient outcomes.

Circulating tumor DNA (ctDNA), fragmented DNA with an average size of 166 bp, is released by cancer cells into circulation. Circulating tumor cells (CTCs) are rare malignant cells detached from tumors which enter the bloodstream. Both these biomarkers can be used for prognosis and the dynamic monitoring of disease progression.

In the MAGIC trial, patients with tumor that are MSI-H or MMRD, had survival rates superior to those with MSS/MSI-L or MMRP tumors when treated with surgery alone.

We will combine dMMR/MSI status with the dynamic evaluation of CTCs and ctDNA using liquid biopsy technology to determine whether changes in tumor burden in response to NTC can identify potential treatment responders.

Sequential peripheral blood samples for CTCs and ctDNA analysis will be taken before and after NCT, as well as one week after surgery.

Tumor assessments will be performed after 2 cycles NCT based on RECIST v1.1 criteria using CT/MRI scan.


Study Type : Observational
Estimated Enrollment : 80 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Study of Molecular Evaluation of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
Actual Study Start Date : November 22, 2017
Estimated Primary Completion Date : December 31, 2018
Estimated Study Completion Date : December 31, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stomach Cancer




Primary Outcome Measures :
  1. The relationship between dMMR/MSI status and response to neoadjuvant chemotherapy [ Time Frame: November 22, 2017 to December 31, 2018 ]
    The relationship between dMMR/MSI status and response to neoadjuvant chemotherapy

  2. The concordance and accuracy of response evaluation results determined by ctDNA, CTCs compared with imaging and serum tumor biomarkers(CEA, CA19-9,CA72-4 et al) [ Time Frame: November 22, 2017 to December 31, 2018 ]
    The concordance and accuracy of response evaluation results determined by ctDNA, CTCs compared with imaging and serum tumor biomarkers(CEA, CA19-9,CA72-4 et al)


Secondary Outcome Measures :
  1. Prognostic values of the CTCs,ctDNA and dMMR/MSI testing [ Time Frame: November 22, 2017 to December 31, 2018 ]
    Prognostic values of the CTCs,ctDNA and dMMR/MSI testing

  2. The concordance of mutations in tumor tissue and ctDNA [ Time Frame: November 22, 2017 to December 31, 2018 ]
    The concordance of mutations in tumor tissue and ctDNA


Biospecimen Retention:   Samples With DNA
blood samples; formalin-fixed, paraffin-embedded tumor blocks


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
locally advanced gastric cancer patients without distant metastasis or peritoneal dissemination defined as cTNM stage of T4a/T4bN+M0
Criteria

Inclusion Criteria:

  1. Ambulatory males or females, age ≥ 18 years
  2. Karnofsky Performance Score (KPS) ≥70% or ECOG performance status: 0 or 1
  3. Pathologically confirmed gastric adenocarcinoma (regardless of degree of histologic differentiation) or adenocarcinoma with signet-ring cell carcinoma , mucinous adenocarcinoma
  4. Clinical Preoperative Stage cT4a/T4bN+M0 disease, including T4b、Bulky-N2, confirmed by CT/EUS
  5. Adequate organ function as defined below: Hemoglobin ≥ 9 g/dl, Hematologic Absolute Neutrophil Count (ANC) ≥ 1.5*109/L, Platelets ≥ 100*109/L, Aspartate Aminotransferase(AST) and Alanine Aminotransferase(ALT)≤ 2.5×ULN, Alkaline pPosphatase( ALP) ≤ 2.5×ULN, Total Bilirubin (TBIL)≤ 1.5×ULN, Renal Serum Creatinine < 1.5 ULN, Serum Albumin ≥ 30g/l.
  6. No serious concomitant disease that make survival period < 5 years
  7. No pleural effusion, no ascites exceeding the pelvis and no metastasis to the peritoneum, liver or other distant organs are confirmed by abdominal pelvic CT.
  8. Planning to undergo gastric cancer D2 surgery after neoadjuvant chemotherapy
  9. No prior antitumor treatment is allowed, including chemotherapy, radiotherapy, immune therapy or target therapy
  10. No mechanical obstruction.
  11. Negative serum or urine pregnant test within 7 days prior to randomization for child-bearing age women
  12. Sexually active males or females willing to practice contraception during the study until 30 days after end of study.
  13. Subjects has to voluntarily join the study and sign the Informed Consent Form for the study

Exclusion Criteria:

  1. Female in pregnancy or lactation, or refuse to receive Contraception measures during chemotherapy
  2. With distant metastasis or peritoneal dissemination diagnosed by CT/EUS
  3. Underwent prior antitumor treatment, including chemotherapy, radiotherapy, immune therapy or target therapy
  4. Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety (including current active hepatic, biliary, renal, respiratory disease, uncontrolled diabetes hypertension et al)
  5. Clinically serious cardiac disease or pulmonary dysfunction.
  6. Patients require emergency surgery with complications (bleeding, perforation and obstruction) caused by gastric cancer
  7. Other complications that cause no radical resection
  8. Serious concomitant disease that make survival period < 5 years
  9. No detection of CTCs or ctDNA in peripheral blood samples before NCT be enrolled in other clinical trials
  10. Allergic reaction to S-1 or oxaliplatin
  11. Abnormal GI tract function
  12. Refuse to provide blood/tissue sample
  13. Sexually active males or females refuse to practice contraception during the study until 30 days after end of study.
  14. Person with no capacity (legally) or inappropriate to continue study treatment for ethics/medical reasons.
  15. Other situation to be judged not adaptive to the study by investigators

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03425058


Contacts
Contact: Tao Fu, MD +8601088196970 Futao916@163.com
Contact: Zhaode Bu, MD +8601088196945 buzhaode@cjcrcn.org

Locations
China, Beijing
Beijing Cancer Hospital Recruiting
Beijing, Beijing, China, 10000
Contact: Fu Tao, MD    +8601088196970    Futao916@163.com   
Contact: Zhaode Bu, MD    +8601088196945    buzhaode@cjcrcn.org   
Sponsors and Collaborators
Beijing Cancer Hospital
Investigators
Study Chair: Jiafu Ji, MD Beijing Cancer Hospital

Responsible Party: Jiafu Ji, Professor, Beijing Cancer Hospital
ClinicalTrials.gov Identifier: NCT03425058     History of Changes
Other Study ID Numbers: 2017YJZ38
First Posted: February 7, 2018    Key Record Dates
Last Update Posted: February 8, 2018
Last Verified: February 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jiafu Ji, Beijing Cancer Hospital:
Molecular Evaluation
Locally Advanced Gastric Cancer
Neoadjuvant Chemotherapy
ctDNA
CTC
dMMR/MSI

Additional relevant MeSH terms:
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases